CARL ALLEN to Alemtuzumab
This is a "connection" page, showing publications CARL ALLEN has written about Alemtuzumab.
Connection Strength
0.393
-
Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies. Blood. 2018 09 27; 132(13):1438-1451.
Score: 0.144
-
High Incidence of Autoimmune Disease after Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease. Biol Blood Marrow Transplant. 2018 08; 24(8):1643-1650.
Score: 0.141
-
Alemtuzumab and CXCL9 levels predict likelihood of sustained engraftment after reduced-intensity conditioning HCT. Blood Adv. 2023 07 25; 7(14):3725-3734.
Score: 0.051
-
A consensus review on malignancy-associated hemophagocytic lymphohistiocytosis in adults. Cancer. 2017 Sep 01; 123(17):3229-3240.
Score: 0.033
-
Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab. Pediatr Blood Cancer. 2013 Jan; 60(1):101-9.
Score: 0.023